BIOCORP
19.9.2022 07:31:35 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and SANOFI announced the completion of the development of SoloSmart® today, on the opening of the EASD (European Association for the Study of Diabetes) annual meeting in Stockholm, Sweden. SoloSmart® is fully compatible with the pharmaceutical group's SoloStar® injection pens.
The result of the collaboration initiated in 2019 between the two companies is presented as an accessory to the Sanofi SoloStar®/ DoubleStar® insulin pens, which records information about the insulin dose, time and date of each injection and transmits it via Bluetooth to a compatible mobile application. The SoloSmart® device automatically and accurately records injected doses, eliminating the need for manual logbooks and possibly allows for adapting to new patient uses of continuous glucose monitoring systems or connected BGM.
Developed by BIOCORP's R&D department, SoloSmart® meets the latest requirements of the new European medical device regulation. Its commercial launch will begin early 2023 in the distribution networks approved by SANOFI and its partners. This partnership strategic step validates a substantial milestone - more details will be given on September 29th (half year results).
Eric Dessertenne, CEO of BIOCORP, said: "The expertise we have developed with Mallya leads us to improve and develop a new device by miniaturizing it, keeping data reliability. We are today very proud of developments achieved by our respective R&D and to present them today at the EASD, which brings together an international diabetes community. The strength of this industrial and commercial partnership has resulted in a technological achievement which will allow people living with diabetes, users of SoloStar® pens, to benefit from a solution that improves their daily life thanks to a presentation that is very compact but still secure and accurate.”
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220918005029/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HistoSonics Opens Expanded Histotripsy Training Center in Hong Kong20.7.2026 14:00:00 CEST | Press release
HistoSonics today announced the opening of its expanded Histotripsy Training Center in Hong Kong, reinforcing the city's position as a leading hub for physician education, clinical collaboration, and innovation in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720812810/en/ Pictured at the expanded Histotripsy Training Center in Hong Kong. Front row (left to right): Dr. Angus Yuen, Chief Medical Officer, Gleneagles Hospital Hong Kong; Prof. Albert Chan, Director of Liver Cancer Surgery Centre, Gleneagles Hospital Hong Kong; Dr. Kenneth Tsang, Regional Chief Executive Officer, IHH Healthcare North Asia, and Chief Executive Officer, Gleneagles Hospital Hong Kong; Dr. Vince Lau, Director of Interventional Radiology Centre, Gleneagles Hospital Hong Kong; Dr. Joe Herman, Vice President, Medical Affairs, HistoSonics. Back row (left to right): Jay Lee, APAC Regional Manager, HistoSonics; Eric Kwong, Hong Kong Sales Manager
Shaping a Generation Through Dialogue: Inside the Doha Debates Ambassador Program20.7.2026 13:29:00 CEST | Press release
Applications are open for young people from around the world to learn to engage and lead through truth-seeking conversations about complex global issues In a world shaped by change and competing narratives, the ability to listen, question and engage in constructive dialogue has never been more critical. Through the Doha Debates Ambassador Program, a production of Qatar Foundation, young people from around the world are not only learning these skills, but actively applying them in their communities, careers and areas of study. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720452437/en/ Shaping a Generation Through Dialogue: Inside the Doha Debates Ambassador Program. Applications are open for young people from around the world to learn to engage and lead through truth-seeking conversations about complex global issues. (Photo: AETOSWire) This online educational program teaches young people from across the globe to debate d
Kinaxis Appoints Herb Yeh as Chief Financial Officer and Chief Strategy Officer20.7.2026 13:01:00 CEST | Press release
Seasoned corporate finance veteran brings more than 25 years of experience working with enterprise software companies through growth, M&A, and strategic transformation Kinaxis® Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today announced the appointment of Herb Yeh as Chief Financial Officer and Chief Strategy Officer, effective July 27, 2026. In this role, Yeh will oversee the global finance organization and corporate strategy operations at Kinaxis, leading all Finance, Accounting, Investor Relations, Corporate Strategy, and Corporate Development. He will work closely with the executive leadership team and Board of Directors to support disciplined execution, long-term growth, and shareholder value creation. "Herb has spent his career working with boards and management teams at their most critical inflection points in enterprise software, and we are thrilled to have him join Kinaxis," said Razat Gaurav, Chief Executive Officer of Kinaxis. "He has followed
IFF Announces Agreement to Sell Its Portfolio of Botanical Extracts, Vitamins & Minerals and Food Enhancement Activities to SuanNutra, a Portfolio Company of Carbyne Equity Partners.20.7.2026 12:45:00 CEST | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, and health and biosciences — today announced that it has entered into an agreement with SuanNutra, a Carbyne Equity Partners portfolio company and global provider of science-backed branded and functional ingredients, to sell its portfolio of botanical extracts, vitamins and minerals, and food enhancement activities, including its range of natural colors and antioxidants and certain localized flavor activities in Peru. The portfolio serves a broad range of food, beverage and nutritional end markets through a comprehensive selection of customized solutions. “These businesses are highly respected, and we are confident they will continue to thrive under the ownership of SuanNutra and Carbyne,” said Erik Fyrwald, CEO IFF. “This transaction is another step in optimizing our portfolio and reinforces our focus on our core innovation-led businesses — Taste, Scent and Health & Biosciences — where we see the greatest opportunities to drive
NIQ Appoints Irina Stoian as Chief AI Commercial Officer20.7.2026 12:45:00 CEST | Press release
New executive role strengthens NIQ’s AI strategy and advances the company’s position as a trusted intelligence infrastructure powering AI-driven commerce NIQ today announced that Irina Stoian has joined the company as Chief AI Commercial Officer, a newly created role designed to accelerate NIQ’s enterprise AI commercial strategy and help clients turn the company’s AI capabilities into business impact and growth. Stoian will help align Product, Technology, Commercial, Partnerships, and Marketing around a unified AI growth strategy. Her remit includes shaping commercial AI offerings, strategic partnerships, pricing and business models, and deeper integration of NIQ capabilities into client workflows. The appointment builds on NIQ’s broader AI strategy, which positions the company as a trusted intelligence infrastructure powering AI-driven commerce. Across its AI portfolio, including ConnectAI, NIQ Optiq™, and NIQ Cadence™, NIQ is expanding how clients access trusted data, intelligence, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom